clinical trial · NCT06365437
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
Kidney TransplantationTCD601Tacrolimus (TAC)Corticosteroids (CS)Mycophenolate Mofetil (MMF)ATG
brief summary
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
started
Jun 6, 2021
primary completion
Dec 11, 2024
completion
Dec 11, 2024
last updated
Mar 12, 2026
official title
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601 (Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant Recipients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol